Mouse Anti-Human EVA1 (Epithelial V-like antigen 1)
Product number PDZMM134
Host species Mouse
Target species Human
Suitable for: IHC-P, WB, ELISA, Immunomicroscopy, Dot blot, ICC, IHC-Fr
Immunogen A KLH-conjugated synthetic peptide derived from human Epithelial V-like antigen 1 protein was used for immunization.
Storage instructions Shipped at 4 °C. Store at -20 °C. Avoid freeze/thaw cycle. Please see notes section.
Storage buffer pH: 7.4, Preservative: Stabilizer, Constituents: PBS 0.01mM
Purity immunogen affinity or SpG purified
Purification notes This product was prepared by immunoaffinity chromatography using immunogen peptide coupled to Sepharose 4B.
Conjugation notes –
General notes For extended storage aliquot contents and freeze at -20 °C or below. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4 °C as an undiluted liquid. Dilute only prior to immediate use.
Our customer’s feedback says the antibody worked great. If in case the antibody fails to give results then please contact our scientific support team for assistance.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end-user.
Product Usage Information:
Western Blotting 3-5 ug/ml
Immunohistochemistry (Paraffin) 5-10 ug/ml
Immunohistochemistry (Frozen) 5-10 ug/ml
Immunofluorescence 5-10 ug/ml
Flow Cytometry 5-10 ug/ml
Please note: All products are “FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES”
Epithelial V-like antigen 1 (EVA1) expression is increased in hepatocellular carcinoma (HCC) and is associated with a poor prognosis and recurrence in HCC patients. Overexpression of EVA1 promotes cell growth, invasion and migration in vitro. EVA1 is able to upregulate the expression of genes in the ERBB3-PI3K pathway.
Terms and conditions
Guarantee only valid for products bought direct from PADZA or one of our authorized distributors
EVA1 (CLL cells)
Note: This product has originally been developed at Avicenna Research Institute, Tehran, IRAN and assigned to PADZA Company according to contract 98/15/191dated 98/01/10.